10 À4 AE210 À5 ) for a1205 nt region. Our approach represents atime-and cost-ef-fective improvement over current methods, and can be adapt-ed for genomic studies requiring artifactand bias-free selec-tive amplification, such as microbial pathogens, or rare cancer cells.
Viruses pose acontinuing threat to public health due to vari-ous compounding factors, including alack of effective treat-ment, their rapid evolution, and the difficulty of characterizing rare but potentially lethal strains.
[1] Although recombinant mu-tations are very infrequent, they have the potential to generate dangerous, virulent strains, because the largescale exchange of genetic material can provide adaptations to escape immune systems and resist treatment.
[2] To more effectively combat such lethal adaptations abetter understanding of viral recombination is required;however,currentgenomic sequencing techniques involveamplification artifacts that obscure rare mu-tations, and amplification bias complicatesdetermining their frequencies of occurrence. [3] The major limitations for studyingribonucleic acid (RNA) viral recombinants arise from the unavoidable genomic am-plification step precedingthe sequencing.When amplifying rare recombinanttemplates in the presence of their parental genomes,template switching can occur during reversetran-scription(RT) andPCR, thereby resulting in aconcatenation of two parental fragments. These artificial recombinants are knownaschimeras, and they are indistinguishable from true biological recombinants (see Figure S1 in the Supporting Infor-mation).
[4] Chimeras can be avoided in emulsionPCR [5] by dilut-ing the templatesothat drops contain at most asingle tem-plate (Table S1 ).However,emulsion PCR cannot overcome am-plification bias and sequencing bias, which prevent sequencing methods from quantifying recombinant subpopulations.
[6] To overcome counting bias, on-chip digital PCR [7] maybeused to count the number of true recombinants in asample;however, digitalPCR is limited in the number of samples it can test and does not have the capability to retrieve the contentofampli-fied samples for sequencing (Table S1 ). Thus, amethod that can both count and sequence rare recombinantswill improve our understanding of viral recombination, therebyleadingto better antiviral drugs and vaccines. Drop-based microfluidics (DBM) is arapidly emerging tech-nique whereby micron-sized aqueous drops immersed in an inert carrier oil are used as vessels for biological experiments. [8] The drops are surrounded by surfactants carefully chosen to preventd rop coalescence or surface adsorption of biological molecules. Individual drops can be filled, steered, split, combined, detected, and sorted in am icrofluidic device at thousands per second, [9] and their content is easily retrieved for downstream analysisb ys eparating the emulsion. The small volumeo ft hese drops (~10 pL) is ideal fori solating single molecules and assaying them with minimal background noise. Hence DBM is ideal for developing ap latform to amplify single templates for both counting and downstream sequencing.
Here we developed aDBM technique that addresses the limitationso fc urrent assays for characterizing and quantifying rare genomes:s ingle templates are isolated, individually amplified in drops, andt hen placed in microwellsf or processing. By detecting, sorting, and consensus sequencing the amplicons, we unambiguously determined both recombination frequency and loci ( Figure 1A ). We demonstrate our techniqueb ya ccurate characterizationo fr ecombinant progenyf rom two RNA murinenorovirus (MNV)strains,MNV-1 and WU20, by co-infecting am urine RAW264.7 macrophage culture. This platform decreasest he artifacts produced duringR T, PCR amplification, and sequencing to an arbitrarily low value.
To determine the concentration of the parental strains, we co-encapsulated viral templates with Taqman probe (Life Te chnologies) in 8.25 pL drops and performed off-chip amplification. This probe fluoresces only in the presence of viral templates (brighta nd dark drops in Figure 1C ). We injected the drops into ar eading and sorting device ( Figure 1A4 ), ando btained distributions of size and intensity ( Figure 2A ). The average number of templates per drop (l)d ecreases with the dilution factor (X)a ccording to l = cV/X,w here c is the stock concentration and V is the volume of the drop. The number of templates in any drop( n)f ollows aP oissond istribution (p n = l n e Àl /n!). [10] As l approaches 0, this distribution is binary because the probability of ad rop containing multiple templates is negligible. Accordingly, l approaches the ratio of bright drops (whichc ontain one template) to dark drops (no template): l = N + /N À .T he data from the dilution series fit this linear relationship well, and we obtained viral stock concentra- Figure 1 . Method overview. A) Schematic of experimental flow.1)Viral recombinants are generated by co-infecting aRAW 264.7 cell culturewith two MNVparentalstrains, MNV-1 and WU20; 2) Single viral genomesfrom cell lysate are mixed with aone-step RT-PCR solution and aDNA-intercalatingdye;viral solution is injected into amicrofluidic drop-maker device;the oil streams then pinch off this viral solution for encapsulation in picoliter water-in-oild rops. 3) Collection of the generated drops and thermocycling off-chip to amplifythe recombination fragments. 4) Re-injection of drops into am icrofluidic fluorescent drop reader and sorter;drops containinga mpliconsfrom the recombinant genomes (bright) are sorted. 5) Distribution of sorted bright drops into a9 6-wellp late. 6) Second-roundP CR, extraction of ampliconsoft he correct length from the gel, andsubmission to Sanger sequencing. 7) The region of template switching between parental genomes is determined by comparing the recovered sequence against the two reference genomes. B) Image of the microfluidic dropmaker device.T wo oil streams (O) pinch off the flowing viral solution (W), for encapsulationi npicoliter water-in-oil drops(seealso Figure S2 tions: c MNV-1 = 9.4 10 9 and c WU20 = 4.7 10 10 genome copiesp er mL ( Figure 2B ). Assuming ac onversion factor of 1PFU (plaque-forming unit) per 100 viral genomes, [11] these concentrationsa re consistent with their infectivity titers (10 8 and 5 10 8 PFU mL À1 ,respectively). We modified the above assay to determine the concentration of recombinants resulting from am acrophage cell-culture co-infected with am ixture of both parental viruses, each with am ultiplicity of infection of 2. We use ao ne-step differential RT-PCR cocktail [12] where each of the two primers is specific to only one parental virus, in order to selectively amplifyt hose recombinants where template switchingo ccurs in as elected 1205 bp region ( Figure 3A ;t he top row of the gels confirms that our cocktail amplified recombinants from the co-infection withouta mplifying parental viruses in the viral mixture). For our drop-based assay,t he differential RT-PCR cocktail wasc oencapsulated with viral templates, and in-dropR T-PCR was performedo ff-chip. In order to registera mplicons, the cocktail was supplemented with aD NA-intercalating dye, EvaGreen (Biotium, Hayward, CA). We observedabroad distribution of fluorescent drops, as expected when using an on-specific DNA probe that registers both specific and non-specific target amplification ( Figure 3B) .
To increase the fidelity of our recombinant assay and exclude false bright drops containing non-specific ampliconsw e used ag el-verification procedure. Drops whose fluorescence exceeded the threshold (F 0 = 9.5;F igure 3B)w ere sorted in amicrofluidic device. The sorted drops were mixed with asufficient volume of bufferd rops and distributed into many microwells, such that at most one fluorescent drop was in each well. As econd round of differential in-wellP CR was performed to produce enougha mplicons for gele lectrophoresis, in order to select drops containing amplicons of the right length (Figure 1E) . The fluorescencet hreshold for sorting wass et sufficiently lowt om inimize loss of drops containing recombinants (absence of av isible target band for drops with F < F 0 ;F igure 3A,l ower gels). Discarding recombinants of the wrong length is justifiedb ecause only potentially viable viruses are considered; [13] however,a mplicons of the right length are not guaranteed to be true recombinants as they could be the result of in-drop chimera generation.
Because in-drop chimera generation requires the presence of multiple templates in the same drop, chimera generation can be sufficiently repressedb yd iluting the template such that the probability of any drop containingm ultiple templates is negligible. We assayed ad ilution series of ar ecombinantfree mixture of both parental viruses, where target amplicons can only result from in-dropc himera generation.F or l ! 0.3, the fraction of gel-verified drops exhibits aq uadratic trend, R chimera / l 2 ,w hich is expected in the limit of small l,a nd is shownb yt he filled blue squares and solid blue line in Figure 3C .W efound no chimera drops for l = 0.02 and 0.1, thus establishing as afe range forchimera-free RT-PCR.
We determined the recombination frequency (the fractiono f recombinant genomes produced in one virus replication cycle) in co-infected cells from ad ilution series experiment with at wo-stepr ecombinanta ssay.T oe stimate the recombinant frequency we made two assumptions:t he viral yield of the infection far exceeds that of the initial inoculum, and almosta ll of the cells are infected by both strains due to the high viral loading. The recombination frequency (P rec )i st hus the ratio of the fraction of recombinant drops (R rec )t ot he concentrationo f parental virus, l (solid triangles in Figure 3C ). To correct for chimeras, we estimated the chimera frequency (R chimera )f rom the ratio of the fractiono fg el-verified chimera drops (blue squares in Figure 3C )tothat of drops containing both parental viruses ((1Àe À(l/2) ) 2 )a nd obtained P chimera = R chimera /(1Àe À(l/2) ) 2 = 1.2 10 À4 AE 110 À5 (squaresi nF igure 3D). Accordingly the corrected recombinantf requency is P rec = (R rec ÀR chimera )/l = 3.3 10 À4 AE 210 À5 (trianglesinFigure 3D). For ad etailed analysiso fr ecombinants we used Sanger sequencing with ampliconsf rom nine gel-verified drops isolated in microwells;w eo btained unambiguous traces, similar to those for clone-based sequencing. [14, 15] The sequences align with WU20 genome at the 5'-end, and with MNV-1 at the 3'-end;i nb etween is the region of recombination where template switching occurred. We identified four unique regionsi nt he sequenced drops (Figure S3 ). For example, the region of recombination of Drop-1 spans nucleotides 4950-4968 and for Drop-9 it spans nucleotides 5240-5255 ( Figure 4A and B) . Interestingly,D rop-9 also includes as ynonymous transversion at nucleotide 5221. Using this method, the first recombinant (from Drop-1 sequence) was also detected from in vivo samples by examining the feces of mice that were co-infected with both parental strains. [12] Our drop-based microfluidics technique combines two novel steps to achieve bias-and artifact-free characterization of rare RNA recombinants in the presenceo falarge background of genomic material. Single-step in-dropd ifferential RT-PCR faithfullyr eplicates low-abundantt arget templatesw ith negligible chimera generation.S ubsequent screening isolates single drops containing recombinanta mpliconsf or consensus sequencing to provideb ias-free genomic data. To our knowl- edge, this is the first use of in-drop single-step RT-PCR with an on-specific fluorescent probe;t his is essential for assays such as our search forr ecombinants where the target sequencei su nknown. The continuous isolationo fs ingle templates for amplification, detection, and sequencingsr epresents an improvement over all methods for characterizingr are recombinant templates (Table S1 ) and provides detailed information on both the frequency and diversity of recombinants. [15, 16] Moreover,o ur technique can be adapted for studies of nonspecific rareg enomic events, such as lateral gene transfer in bacteria,h omologous recombination in parasites, andV (D)J recombination in the mammalian immune system. [17] Experimental Section
Experimental details can be found in the Supporting Information.
